Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2012/020844external-prioritypatent/WO2012097012A1/en
Application filed by Cleveland Biolabs IncfiledCriticalCleveland Biolabs Inc
Publication of AR087114A1publicationCriticalpatent/AR087114A1/en
Se refiere a métodos y agentes utilizados para tratar el cáncer en tejidos que expresan el receptor Tipo Toll 5, mediante la proporción de un agonista del receptor Tipo Toll tal como flagelina. Se refiere también a la protección del hígado de una toxicidad hepática utilizando un agonista del receptor Tipo TolI. Reivindicación 1: Un método para tratar el cáncer en un mamífero que comprende administrar a un mamífero que lo necesita un agonista del receptor Tipo Toll (TLR), en donde el cáncer está presente en un tejido que expresa TLR.It refers to methods and agents used to treat cancer in tissues that express the Type Toll 5 receptor, by the proportion of a Type Toll receptor agonist such as flagelin. It also refers to the protection of the liver from liver toxicity using a TolI type receptor agonist. Claim 1: A method of treating cancer in a mammal that comprises administering to a mammal in need thereof a Toll-like receptor agonist (TLR), wherein the cancer is present in a tissue that expresses TLR.
ARP120102493A2012-01-102012-07-10
USE OF THE TOLL TYPE RECEIVER AGONIST FOR CANCER TREATMENT, TREATMENT METHOD
AR087114A1
(en)